May 10 (Reuters) - Novavax Inc said on Monday its combined flu and COVID-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study. (https://refini.tv/3bg25TM) (Reporting by Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 USD | +2.31% | +19.14% | +222.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+222.92% | 2.18B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.93% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax : combined influenza/COVID-19 vaccine shows promise in preclinical study